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Vascularized tumors are exposed to intermittent hypoxia, that is, hypoxia followed by periods of reoxygenation. Abnormal structure and
dysfunction of tumor blood vessels are responsible for these conditions. These repeated short periods of hypoxia concern tumor cells as well as
endothelial cells. However, the effects of intermittent hypoxia are poorly understood. The aim of this study was to investigate the effects of
intermittent hypoxia on endothelial cells and particularly on HIF-1α, a central actor in adaptive response to hypoxia. For that, endothelial cells
were exposed to four repeated cycles of 1-h hypoxia followed by 30 min of reoxygenation. We showed that repeated cycles of hypoxia/
reoxygenation induced a modification in HIF-lα phosphorylation pattern: a progressive increase in HIF-1α phosphorylated form was observed
during the hypoxic periods. Activation of p42/p44, Akt and PKAwas observed in parallel. PKAwas shown to be involved in the phosphorylation
of HIF-lα under intermittent hypoxia, while p42/p44 and Akt were not. As HIF-1 activity is often associated with enhanced cell survival, a better
knowledge of the effects of intermittent hypoxia on endothelial cells and the highlight of particular mechanisms induced by intermittent hypoxia
are essential to understand the behavior of endothelial cells during neo-angiogenesis.
© 2007 Elsevier B.V. All rights reserved.Keywords: Intermittent hypoxia; HIF-1α; PKA; Neo-angiogenesis; Tumor1. Introduction
Solid tumors require, for their continued growth, formation
of blood vessels to insure nutrients and oxygen supply [1,2].
Indeed, beyond a critical size, simple diffusion of oxygen and
nutrients becomes insufficient for tumor development [3,4]. For
then on, tumors express various pro-angiogenic factors which
lead to the formation of new blood vessels from pre-existing
blood vessel cells and/or endothelial precursor cells from the
bone marrow [4–7]. The vessels formed in these circumstances
are described to be structurally and functionally abnormal [3].
Indeed, these tumor blood vessels are often tortuous, dilated,
with uneven diameter, excessive branching and numerous dead
ends [3,8]. Moreover, they are not organized into definitive
venules, arterioles and capillaries like their normal counterparts,⁎ Corresponding author. Tel.: +32 81 72 41 31; fax: +32 81 72 41 35.
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doi:10.1016/j.bbamcr.2007.06.002but share chaotic features of all of them [9–11]. This abnormal
structure of tumor blood vessels and their compression by
proliferating cancer cells induce an irregular blood flow in
tumor which can lead to transient hypoxia [12–16]. This
intermittent hypoxia concerns endothelial cells as well as tumor
cells.
One of the major cell responses to poor oxygen supply is
the activation of hypoxia-inducible factor-1, a central actor in
adaptive response to hypoxia [17]. Hypoxia-inducible factor-1
(HIF-1) is a heterodimeric transcription factor composed of
the HIF-1α (120 kDa) and ARNT (94 kDa) (Aryl hydro-
carbon Receptor Nuclear Translocator; also called HIF-1β)
subunits. These two subunits belong to the Per-Aryl
hydrocarbon nuclear translocator (ARNT)-Sim (PAS)-basic
helix loop helix (bHLH) family [18,19]. HIF-1α and ARNT
are constitutively expressed [20], but the formation of HIF-1
transcription factor in the nucleus depends on HIF-1α
stabilization which is principally O2 dependent [21]. Under
normoxia, HIF-1α is hydroxylated on the proline residues 402
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prolyl-4-hydroxylases [22]. These hydroxylations allow the
binding of pVHL (von Hippel–Lindau tumor suppressor
protein) on the ODD domain of HIF-1α [23]. pVHL acts as a
substrate recognition of the E3 ubiquitin ligase protein
complex [24] and induces the ubiquitination of HIF-1α on
its N- and C-terminal parts (aa 390–417 and 549–582,
respectively) [22]. This ubiquitination targets HIF-1α for
proteasomal degradation. In the other hand, under hypoxic
conditions, the prolyl hydroxylase activity decreases and the
degradation pathway described above is interrupted [25]. HIF-
1α thus accumulates rapidly and translocates in the nucleus
where, after dimerisation with ARNT, it induces target gene
transcription involved notably in glycolysis (e.g. GAPDH)
and angiogenesis (e.g. VEGF) [26], which allows cells to
adapt to hypoxia [27].
Effects of intermittent hypoxia on endothelial cells are
poorly known and in a general way, intermittent hypoxia is
poorly understood. Some data indicates that transient decreases
in blood flow have significant implication for delivery of
chemotherapeutic agents, cellular responsiveness to those
agents, and the regrowth potential of the surviving tumor cells
[28]. Moreover, transient hypoxia could also be able to modify
the sensitivity of cells to radiations [29]. Consequently,
intermittent hypoxia plays an important role in tumor response
to therapies and more largely to cell survival. Unfortunately,
intracellular mechanisms induced by intermittent hypoxia in
tumor cells as well as in endothelial cells are poorly described in
the literature.
So, the aim of this work was to study the effects of
intermittent hypoxia on endothelial cells and particularly on
HIF-1, the central regulator of cell adaptation to hypoxia.
Intermittent hypoxia is described in the literature as a
recurrent phenomenon inside vascularized tumours and com-
posed of relatively short periods of hypoxia and reoxygenation
[14,30–33]. Therefore, considering these data as well as the
work of Martinive et al. [34], the effect of intermittent hypoxia
was studied exposing endothelial cells to cycles of 1 h hypoxia
followed by 30 min reoxygenation.
2. Materials and methods
2.1. Cell culture
EAhy926 endothelial cells [35] were maintained in Dulbecco's Modified
Eagle Medium (DMEM) (4.5 g/L D-glucose) without L-glutamine and sodium
pyruvate (Invitrogen) containing 10% (v/v) calf bovine serum (Invitrogen) and
penicillin (50,000 units/l)–streptomycin (50,000 μg/l) (Invitrogen).
HMEC-1 endothelial cells were maintained in MCDB-131 Medium
(Invitrogen) containing 10 ng/ml endothelial cell growth supplement (Sigma),
1 μg/ml hydrocortisone (Sigma), 10 mM L-glutamine (Sigma), and 15% (v/v)
calf bovine serum (Invitrogen).
Hypoxia (1% O2) incubations were performed in serum-free CO2-
independent medium (Invitrogen) supplemented with 50,000 units/l of
penicillin, 50,000 μg/l streptomycin, and 10 mM L-glutamine (Sigma) by
exposing the cells to an atmosphere containing 99% N2 and 1% O2. Control
normoxic cells were maintained in normal atmosphere. The level of hypoxia in
the medium in our experimental conditions is 10 mm Hg of dissolved oxygen
within the medium. This level of hypoxia is achieved after about 10 min of
incubation. On the other hand, during reoxygenation, the concentration ofdissolved oxygen reaches 120 mm Hg within 2 min. Two incubation schedules
were performed: chronic or intermittent hypoxia. Under chronic hypoxia, cells
were incubated for a continued period from 1 to 6 h at 1% O2. Under intermittent
hypoxia, cells were subjected to repeated hypoxia (1 h, 1% O2)/reoxygenation
(30 min, 20% O2) cycles with a maximum of 5 consecutive cycles.
2.2. Western blot analysis
Total cell extracts were prepared from EAhy926 or HMEC-1 cells grown in
T25 flasks. Cell medium was replaced by CO2-independent medium, and cells
were incubated in normoxia (20% O2) or Hypoxia (1% O2) with or without
inhibitors [KN93 (Biomol) at 15 μM, SP00125 (Calbiochem) at 20 μM,
Staurosporine (Sigma) at 1 μM, SB203580 (Alexis) at 20 μM, Genistein
(Sigma) at 10 μM, PD98059 (Biomol) at 20 μM, 2-Aminopurine (Sigma) at
10 mM, BAY11-70852 (Calbiochem) at 25 μM, LY294002 (Calbiochem) at
50 μM, H-89 (Biomol) at 20 μM]; or agonist [Iloprost (Cayman) at 100 nM].
After the incubation, cells were lysed using the extraction buffer [Tris 80 mM
pH 7.5 (Merck), KCl 300 mM (Merck), EDTA 2 mM (Merck), Triton X-100 1%
(v/v) (Sigma), containing a protease inhibitor mixture (≪ Complete ≫ from
Roche Molecular Biochemicals, 1 tablet in 2 ml H2O, added at a 1:25 dilution)
and phosphatase inhibitors (NaVO3 25 mM, PNPP 250 mM, β-glyceropho-
sphate 250 mM and NaF 125 mM, at a 1: 25 dilution)]. The lysate was collected
in pre-cooled micro-tube, centrifuged 5 min at 13,000×g, 4 °C and the
supernatant was collected. Extracts were separated on 10% sodium dodecyl
sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE) gels and then
transferred to a polyvinylidene difluoride membrane (Amersham Biosciences).
After blocking in phosphate saline buffer containing 0.1% (v/v) Tween and 5%
(w/v) dried milk, the blot was probed with anti-HIF-1α antibodies (BD-
Transduction Laboratories; diluted 1:2000; secondary antibody was an anti-
mouse horseradish peroxidase-conjugated (Amersham) diluted 1:50,000), anti-
phospho-p42 and p44 MAPKs antibodies (Cell Signaling; diluted 1:20,000;
secondary antibody was an anti-rabbit horseradish peroxidase-conjugated
(Amersham) diluted 1:200,000); anti-ERK-1 antibodies (Transduction Laboratories;
diluted 1:20,000; secondary antibody was an anti-mouse horseradish peroxidase-
conjugated (Amersham) diluted 1:200,000); anti-ERK-2 antibodies (Transduction
Laboratories; diluted 1:20,000; secondary antibody was an anti-mouse horseradish
peroxidase-conjugated (Amersham) diluted 1:200,000); anti-α-tubulin antibo-
dies (Sigma; diluted 1:40,000; secondary antibody was an anti-mouse horse-
radish peroxidase-conjugated (Amersham) diluted 1:200,000); anti-phospho-
AKT (ser 473) antibodies (Cell Signaling; diluted 1:10,000; secondary antibody
was an anti-mouse horseradish peroxidase-conjugated (Amersham) diluted
1:50,000); anti-AKT antibodies (Cell Signaling; diluted 1:10,000; secondary
antibody was an anti-rabbit horseradish peroxidase-conjugated (Amersham)
diluted 1:50,000); anti-phospho-CREB antibodies (Upstate; diluted 1:10,000;
secondary antibody was an anti-rabbit horseradish peroxidase-conjugated
(Amersham) diluted 1:50,000); anti-CREB antibodies (Cell Signaling; diluted
1:5000; secondary antibody was an anti-rabbit horseradish peroxidase-
conjugated (Amersham) diluted 1:50,000); anti-Aldolase antibodies (Chemicon
international; diluted 1:500; secondary antibody was an anti-goat horseradish
peroxidase-conjugated (Amersham) diluted 1:50,000). Chemiluminescent
detection was performed with ECL Advance™ western blotting detection kit
(Amersham Biosciences). All the experiments have been performed 2 or 3 times.
One representation is shown in each figure.
2.3. λ-protein phosphatase (λ-PPase) treatment
40 μg proteins of total cell extracts for western blot were incubated at 30 °C
during 60 min in the presence or not of 100 units of lambda protein phosphatase
(New England Biolabs) and 1× λ-PPase reaction buffer supplemented with
2 mMMnCl2 (New England Biolabs). These samples were used immediately to
perform a western blot analysis, as described here above.
2.4. PKA kinase activity assay
EAhy926 cells were grown in T75 flasks. Cell medium was replaced by
CO2-independent medium and cells were incubated under intermittent hypoxia
with or without H-89 (Biomol) at 20 μM. After the incubation, the medium was
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[20 mMMOPS (Merck), 50 mM β-glycerophosphate (Prolabo), 50 mM sodium
fluoride (Merck), 1 mM sodium vanadate (Sigma), 5 mM EGTA (Sigma), 2 mM
EDTA (Merck), 1% (v/v) NP40 (Sigma), 1 mM dithiothreitol (DTT) (Sigma),
1 mM benzamidine (Sigma), 1 mM phenylmethanesulphonylfluoride (PMSF)
(Sigma) and protease inhibitors 4% (v/v) (Complete®; Roche)] was added per
T75 flask and the flasks were put on ice. After 10 min incubation period, cells
were scraped using a rubber policeman/cell scraper and cell lysates were
collected in a pre-chilled 1.5 ml microtube kept on ice and then sonicated
3×20 s. Microtubes were centrifuged at 13,000×g for 15 min at 4 °C. Clear
supernatant was transferred to a pre-chilled 1.5 ml microtube and proteinFig. 1. Effect of hypoxia–reoxygenation (H–R) cycles on the abundance of the H
(A) EAhy926 cells were incubated during increasing times under cycles of hypoxia (H
hypoxia (CH). After the incubation, total cell lysates were recovered for western blottin
is representative of three independent experiments. (B) The optical density (O.D.) for e
upper band and the O.D. of the corresponding lower band were reported on graph (n
intermittent hypoxia and total cell lysates were treated or not with aλ-protein phosphat
by western blotting with antibodies against HIF-1α and α-tubulin used as loading coconcentration was determined using Bradford method. The assay was performed
immediately after cell lysis using a PKA Kinase Activity Assay Kit (Non-
Radioactive) (Stressgen BIOREAGENT) with 40 μg of fresh lysate proteins for
each condition.2.5. Total RNA extraction
EAhy926 endothelial cells were grown in T75 flasks. Cell medium was
replaced by CO2 -independent medium and cells were incubated under
intermittent or chronic hypoxia for periods of time from 1 to 7 h. After theIF-1α phosphorylated (P-HIF-1α) and non-phosphorylated (HIF-1α) forms.
, 1 h)–reoxygenation (R, 30 min.) or during 5.5 h under normoxia (N) or chronic
g with antibodies against HIF-1α andα-tubulin used as loading control. This blot
ach band onwestern blot analysis was determined. Ratios between the O.D. of the
=3). ⁎⁎pb0.01 vs. H cycle 1 (Student's t test). (C) Cells were incubated under
ase and incubated or not during 1 h30 at 30 °C. These samples were then analysed
ntrol.
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performed using RNAgents kit according to the manufacturer's instructions
(Promega).
2.6. Reverse transcription
For each condition, 2 μg of total RNA were mixed with 2 μl oligo (dT)
(12–18) (500 ng/μl) (Gibco). The volume was then brought up to 9 μl with
nuclease-free water (Promega). This mix was incubated 10 min at 70 °C and
then put on ice for 5 min. 9 μl of reaction mix [4 μl Buffer RT 5X
(Promega); 2 μl DTT 0,1 M (Promega); 1 μl RNAsin (40U/μl)(Promega); 2 μl
dNTP mix (Eurogentec)] were added and the samples were incubated 5 min at
room temperature. After addition of 1.5 μl SuperScriptRII (200U/μl) (Invitro-
gen), the samples were incubated 90 min at 42 °C and then 15 min at 70 °C.
Finally, 1 μl of Ribonuclease H (2U/μl) (Gibco) was added and the samples were
incubated 20 min at 37 °C before to be stored at −20 °C.
2.7. Realtime RT-PCR
The levels of aldolase transcripts were determined by real time
reverse transcriptase (RT)-PCR. cDNA (5 μl) previously obtained by
reverse transcription of total RNA was mixed to SYBR Green Master
Mix PCR [2.5 μl distilled water, 1.7 μl of primer Reverse at 9 μM;
1.7 μl of primer Forward at 9 μM; 12.5 μl of SYBR green]. PCRs were
carried out in a real time PCR cycler (ABI PRISM 7700 Sequence
Detector, PE Applied Biosystems). Thermal cycling conditions were: initialFig. 2. Effect of Hypoxia–Reoxygenation cycles on p42 and p44 MAPK phosphor
(H, 1 h)–reoxygenation (R, 30 min) cycles. After each step of the kinetics, total cell
MAPK (P-p42), phospho-p44 MAPK (P-p44), p42 MAPK total, and α-tubulin used
bands on the western blot analysis from Awere determined. The O.D. values for botincubation of 10 min at 95 °C, followed by 40 cycles of 30 s at 95 °C,
1 min at 57 °C annealing temperature, and 30 s at 72 °C. Samples were
compared using the relative Ct method. To normalize for input load of cDNA
between samples, α-tubulin was used as an endogenous standard. Specific
primers were used: aldolase forward 5′-TGCGCAGGAGGAGTATGTCA-3′;
aldolase reverse 5′-AGGCGTGGTTAGAGACGAAGAG-3′; α-tubulin forward
5′-CCCGAGGGCACTACACCAT-3′; α-tubulin reverse 5′-CAGGGAGGT-
GAACCCAGAAC-3′.
2.8. Transfection
To assay HIF-1 transcriptional activity, we used the pGL3-(PGK-HRE6)-
tk-luc reporter vector, which contains 6 HRE cis-elements from the PGK
gene linked to the thymidine kinase basal promoter and to the firefly
luciferase gene [36]. A Renilla luciferase plasmid (pRL, Promega) was used
as the transfection normalization vector. For transfection, 1 μg of plasmid (5/
6 pGL3-(PGK-HRE6)-tk-luc+1/6 pRL) was mixed with 60 μl of OptiMEM
medium (Gibco). 0.6 μl of Superfect (QIAGEN) was then added and the
solution was incubated 15 min at RT. Finally, the transfection solution was
completed with 360 μl of OptiMEM medium containing 5.9% (v/v) FBS.
420 μl of this mixture was dispensed on cells cultured in a 24-well dish and
previously rinsed with PBS. Cells were incubated 3 h at 37 °C, 5% CO2 with
the transfection solution and then rinsed with DHG medium. After
transfection, cells were incubated 24 h at 37 °C, 5% CO2 with DHG
medium containing 10% (v/v) FBS. Before incubation under hypoxia, the
medium was replaced by CO2 independent medium as described previously.ylation. (A) EAhy926 endothelial cells were exposed to four repeated hypoxia
lysates were recovered for western blotting with antibodies against phospho-p42
as loading control. (B) The optical density (O.D.) of P-p42, P-p44 and α-tubulin
h P-p42 and P-p44 were normalized by the α-tubulin O.D. values.
Fig. 3. Effect of p42 and p44 MAPK inhibition on HIF-1α phosphorylation during hypoxia–reoxygenation cycles. EAhy926 endothelial cells were incubated in the
presence or not of PD98059 at 20 μM under intermittent hypoxia. Cell lysates at times 0, 1 h, 4.5 h and 5.5 h were recovered for western blotting with antibodies
against HIF-1α, phospho-p42 MAPK (P-p42), phospho-p44MAPK (P-p44), p42 MAPK total, and α-tubulin used as loading control. This blot is representative of two
independent experiments.
Fig. 4. (A) Effect of hypoxia–reoxygenation cycles on Akt phosphorylation. EAhy926 endothelial cells were exposed to four repeated hypoxia (H, 1 h)–reoxygenation
(R, 30 min) cycles. After each step of the kinetics, total cell lysates were recovered for western blotting with antibodies against phospho-Akt (P-Akt), and Akt total.
(B) The optical density (O.D.) for both P-Akt and Akt-total bands on the western blot analysis from Awas determined. The O.D. values for P-Akt were normalized
by the Akt-total values.
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Fig. 5. Effect of AKT inhibition on HIF-1α phosphorylation during hypoxia–
reoxygenation cycles. EAhy926 endothelial cells were incubated in the presence
or not of LY294002 at 50 μM under intermittent hypoxia. Cell lysates at times 0,
1 h, 4.5 h and 5.5 h were recovered for western blotting with antibodies against
HIF-1α, phospho-Akt (P-Akt), Akt total, and α-tubulin used as loading control.
This blot is representative of two independent experiments.
1563S. Toffoli et al. / Biochimica et Biophysica Acta 1773 (2007) 1558–1571The luciferase activity was quantified in a luminometer using the Dual
Luciferase Assay System (Promega).
3. Results
3.1. Effect of hypoxia–reoxygenation cycles on HIF-1 alpha
phosphorylation
EAhy926 endothelial cells were exposed to intermittent
hypoxia and western blotting analysis was performed for HIF-
1α. Two bands appeared on the western blot; the slower
migrating line being a phosphorylated form of HIF-1α.
Indeed, treatment with a λ-protein phosphatase (λ-PPase) of
samples exposed to four hypoxia–reoxygenation cycles,
induced the shift of the upper band to the lower band on western
blotting analysis. No modification was observed for the lower
band (Fig. 1C).
Cells exposure to hypoxia/reoxygenation repeated cycles
induced an increase in the abundance of HIF-1α protein
during the first three cycles as well as an increase in the
abundance of the HIF-1α-phosphorylated form with respect toTable 1
Effect of different kinase inhibitors on HIF-1α abundance and phosphorylation in E
Inhibitors Targeted Kinases
KN93 Calmodulin Kinases
SP00125 JNK
Staurosporin Protein Kinases
SB203580 P38 MAPK
PD98059+SB203580 MEK and P38 MAPK
Aminopurin Ser/Thr Kinases
BAY11-7082 IKK
H-89 PKA
EAhy926 endothelial cells were submitted to four repeated hypoxia (H, 1 h)–reoxy
(20 μM), staurosporine (1 μM), SB203580 (20 μM), genistein (10 μM), PD98059 (20
lysates were recovered for western blotting with an antibody against HIF-1α.its non-phosphorylated form (Fig. 1A and B). After the first hour
of hypoxia (cycle 1, time 1 h), HIF-1α-non-phosphorylated form
is more abundant (about 60%). On the other hand, after the
fourth hour of hypoxia (cycle 4, time 5.5 h), HIF-1α-
phosphorylated form was predominant (about 70%). Changes
in the respective abundance of these two forms of HIF-1α were
made in a progressive way in the course of hypoxia/reoxygena-
tion cycles. The abundance of the HIF-1α-phosphorylated form
with respect to its non-phosphorylated form, after the fourth
hypoxia–reoxygenation cycle, nearly reached the level observed
for incubation under chronic hypoxia during 5.5 h. No HIF-1α
was observed under normoxia and a complete disappearance of
HIF-1α occurred at each reoxygenation step.
Viability was checked directly after the incubations using
the ethidium bromide/acridine orange staining : about 10% of
the cells were orange stained in all conditions: 5.5 h
normoxia, 5.5 h chronic hypoxia and 4 cycles of intermittent
hypoxia (data not shown). Long range recovery under
normoxia has also been checked by a clonogenic assay: no
difference was observed for cells incubated under normoxia
or intermittent hypoxia after 7 days. The proliferative capacity
of cells that have been incubated 5.5 h under chronic hypoxia
was slightly higher (data not shown). All these results indicate
that intermittent hypoxia did not affect cell viability in our
experiment conditions.
3.2. Activation of MAPK p42 and p44 under intermittent
hypoxia
Both p42 and p44 MAPKs (also respectively called ERK-2
and ERK-1) have been shown to be activated under hypoxia. It
is also well established that ERK-1 can directly phosphorylate
HIF-1α in its carboxyterminal domain [37]. Considering these
data, we wanted to know whether these kinases could be
responsible for the increase in the phosphorylation of HIF-1α
observed under intermittent hypoxia. First, the MAPKs
activation was followed in the course of hypoxia/reoxygenation
cycles. Their phosphorylation state was assessed by western
blot analysis (Fig. 2). A progressive increase in the phosphory-
lated form of both kinases was observed after each hypoxia stepAhy926 endothelial cells under intermittent hypoxia
HIF-1α total abundance
(with respect to the control
hypoxia without kinase inhibitor)
Modification in HIF-1α
phosphorylation pattern
Decrease No
No modification No
Decrease No
Decrease No
Decrease No
Decrease No
Decrease No
No modification Yes
genation (R, 30 min) cycles in the presence or not of KN93 (15 μM), SP00125
μM)+SB203580 (1 μM), aminopurine (10 mM) or BAY11-70852 (25 μM). Cell
1564 S. Toffoli et al. / Biochimica et Biophysica Acta 1773 (2007) 1558–1571when compared to the control (time zero). On the other hand,
reoxygenation step decreased p42/p44 phosphorylation. How-
ever, the initial low phosphorylation state was never reached
again. The parallelism between the increase in p42/p44
phosphorylation and the increase in HIF-1α phosphorylation
was striking.Fig. 6. Effect of PKA inhibition (A, B) or activation (C) on HIF-1α phosphorylati
endothelial cells were incubated in the presence or not of H-89 at 20 μM or iloprost at
lysates at both times 1 h and 5.5 h were recovered for western blotting with antibo
loading control. These blots are representative of three independent experiments.In order to study the possible implication of MAPKs in the
phosphorylation of HIF-1α in the course of hypoxia/reoxygena-
tion cycles, cells were incubated in the presence or not of
PD98059, a MAPKKs inhibitor. MAPKKs phosphorylate and
activate both p42 and p44. Two extreme points of the hypoxia/
reoxygenation cycle kinetics (hypoxia cycle 1 and hypoxiaon during hypoxia–reoxygenation cycles or under chronic hypoxia. EAhy926
100 nM under intermittent hypoxia, chronic hypoxia (HC) or normoxia (N). Cell
dies against HIF-1α, phospho-CREB (P-CREB), CREB and α-tubulin used as
Fig. 8. Effect of Hypoxia–Reoxygenation cycles on PKA activity. EAhy926
endothelial cells were exposed to four repeated hypoxia (H, 1 h)–reoxygenation
(R, 30 min) cycles in the presence or not of H89 at 20 μM. After each step of
hypoxia, total cell lysates were recovered for a PKA Kinase Activity Assay
(Stressgen Bioreagents, Canada). Three separate experiments were performed
and the results are expressed as means±1 SD. ⁎pb0.05 vs. normoxia; (⁎) pb0.05
vs. H cycle 4 (Student's t test).
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ratios between the abundance of HIF-1α-phosphorylated form
and HIF-1α non-phosphorylated form were opposite. PD98059
at 20 μM induced a complete inhibition of p42/p44 phosphor-
ylation at all the time points, as observed on the western blot.
However, we did not notice any difference in the ratio of HIF-
1α phosphorylated form versus its non-phosphorylated form in
the presence of this inhibitor (Fig. 3). These results indicate that
p42 and p44 were not responsible for HIF-1α phosphorylation
under intermittent hypoxia.
3.3. Activation of Akt under intermittent hypoxia
In addition the MAPKs pathway, it is also well established
that the PI3K/Akt pathway can influence HIF-1α stabilization
[38] and HIF-1α activity [39]. In order to study the implication
of this pathway in the modification of HIF-1α phosphorylation
pattern under intermittent hypoxia, Akt phosphorylation was
followed throughout the hypoxia/reoxygenation cycles
kinetics. An increase in Akt phosphorylation under hypoxia
was observed while a decrease occurred when cells were
reoxygenated (Fig. 4). Akt phosphorylation gradually increased
after each hypoxia/reoxygenation cycle under hypoxia as well
as after reoxygenation. Indeed, phosphorylation level never
returned to the one observed under normoxia (time zero). As for
p42/p44 phosphorylation, this modification of Akt phosphor-
ylation in the course of hypoxia/reoxygenation cycle kinetics
paralleled the changes observed for HIF-1α-phosphorylation. In
order to test whether Akt could be responsible for the phos-
phorylation of HIF-1α in these conditions, cells were incubated
in the presence or not of LY294002, a PI3K inhibitor. As for
MAPKs, this experiment was limited to the end points of the
hypoxia/reoxygenation cycles kinetics. As previously observed,
Akt was phosphorylated under hypoxia with an increase in
phosphorylation after 5.5 h with respect to 1 h (Fig. 5). As
expected, Akt phosphorylation decreased in the presence of
LY294002 at all time points.
With regard to HIF-1α, the phosphorylation shift in the
presence of LY294002 between the time 1 h and 5.5 h was again
observed. No difference in HIF-1α phosphorylation with
respect to the conditions without inhibitor could be evidenced.
These results suggest that Akt was not involved in the
modification of HIF-1α phosphorylation pattern in the course
of hypoxia/reoxygenation cycles.Fig. 7. Effect of Hypoxia–Reoxygenation cycles on CREB phosphorylation.
EAhy926 endothelial cells were exposed to four repeated hypoxia (H, 1 h)–
reoxygenation (R, 30 min) cycles. After each step of the kinetics, total cell
lysates were recovered for western blotting with antibodies against phospho-
CREB (P-CREB) and α-tubulin used as loading control.3.4. Implication of different kinases
In order to try to identify the kinase(s) involved in HIF-1α
phosphorylation in the course of hypoxia/reoxygenation
cycles, different inhibitors targeting the “main” cellular
kinases currently described in the literature were tested.
These inhibitors and their target kinases are listed in Table 1.
In this experiment, we focused our attention on the fourth
hypoxia cycle for which, in our experimental conditions, the
HIF-1α phosphorylated form was predominant with respect to
its non-phosphorylated form. Our aim was to observe, in the
presence of a particular inhibitor, a decrease in the proportion
of HIF-1α-phosphorylated form with respect to its non-
phosphorylated form.
An inhibition of HIF-1α stabilization was observed when
PKC or JNK+p42/p44 were inhibited. Whether or not a
decrease of the total abundance of HIF-1α level was observed,
an identical pattern of phosphorylation to what is observed for
the control was still observed in the presence of all these
inhibitors, indicating that these kinases were probably not
involved in the increase in HIF-1α phosphorylation under
repeated hypoxia/reoxygenation cycles. These results are
summarized in Table 1.
3.5. Involvement of PKA
The role of the PKA in HIF-1α phosphorylation during
intermittent hypoxia was then studied. The HIF-1α-phos-
phorylated state was followed in the presence or not of H-89,
an inhibitor of PKA, at cycles one and four. As observed in
Fig. 6A, the phosphorylation shift was observed as previously
in the absence of inhibitor. On the other hand, in the presence
of H-89, the phosphorylation shift did no longer occur and a
decrease in the abundance of the HIF-1α-phosphorylated form
was observed both at 1 h and 5.5 h. Conversely, iloprost, a
Fig. 9. Effect of hypoxia–reoxygenation (H–R) cycles and PKA inhibition on the abundance of the HIF-1α phosphorylated (P-HIF-1α) and non-phosphorylated (HIF-
1α) form in HMEC-1 endothelial cells. HMEC-1 endothelial cells were incubated under normoxia or intermittent hypoxia in the presence or not of H-89 at 40 μM. Cell
lysates at times 1 h and 5.5 h were recovered for western blotting with antibodies against HIF-1α and α-tubulin used as loading control. This blot is representative of
two independent experiments.
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form of HIF-1α (Fig. 6C). Interestingly, under chronic
hypoxia, the inhibition of PKA by the H-89 did not modify
the ratio observed between the abundance of the phosphory-
lated and non-phosphorylated form of HIF-1α (Fig. 6B).
These results suggest that PKA may be involved in the
phosphorylation of HIF-1α under intermittent hypoxia but not
under chronic hypoxia.
In parallel, the phosphorylation of one of the many PKA
substrates, the protein CREB was studied. CREB phosphor-
ylation state after each stage of hypoxia and reoxygenation
of hypoxia/reoxygenation cycles kinetics was followed by
western blotting. In resting conditions, in EAhy926 cells,
CREB was already strongly phosphorylated (Fig. 7). The
first hypoxia induced a marked decrease in CREB phosphor-
ylation. Then, its phosphorylation gradually increased after
each hypoxia period and reached its maximal level in
hypoxia/reoxygenation cycles kinetics after the fourth cycle,
when the HIF-1α-phosphorylated form was the most
abundant. Incubation in the presence of H-89 induced a strong
decrease in CREB phosphorylation under intermittent hypoxia
(Fig. 6A).
In order to study the actual PKA activity in the course of
hypoxia–reoxygenation cycles, a PKA kinase assay was
performed. No significant PKA activity was detected in
normoxia. After the first hypoxia step, PKA activity was
markedly increased with respect to normoxia. This increase in
activity was also observed for the three other hypoxia steps. In
the presence of H-89, after the fourth hypoxia incubation, the
PKA activity was undetectable; indicating that the activity
measured was specific for PKA (Fig. 8). These results indicate
that an increase in PKA activity was observed during the four
periods of intermittent hypoxia, which would be then
responsible for the progressive increase in CREB phosphoryla-
tion as well as in HIF-1α phosphorylation.
HIF-1α phosphorylation under intermittent hypoxia was
also studied in HMEC-1 (human microvascular endothelial
cells). Four cycles of hypoxia–reoxygenation induced an
increased in HIF-1α phosphorylation, as observed inEAhy926 endothelial cells. Moreover, in the presence of
H-89, a decrease in HIF-1α phosphorylation was observed
(Fig. 9). These results indicate that intermittent hypoxia also
modifies HIF-1α phosphorylation pattern in another line of
endothelial cells and that PKA is also involved in these
modifications.
3.6. HIF-1α is transcriptionally active during intermittent
hypoxia
To complete our study, we wanted to investigate whether this
increase in the proportion of the HIF-1α-phosphorylated form
modified HIF-1 transcriptional activity. Indeed, reports in the
literature describe that HIF-1α phosphorylation increases HIF-1
transcriptional activity [37,40].
To be transcriptionally active, HIF-1α needs to localize in
the cell nucleus. Considering this fact, the subcellular localiza-
tion of HIF-1α during both intermittent and chronic hypoxia
was investigated by immunofluorescence analysis. The results
showed that HIF-1α was localized in the nucleus after each
hypoxia cycle. However, after the second and the third cycles,
HIF-1α was also present in the cytosol. Under chronic hypoxia,
HIF-1α was exclusively nuclear (data not shown).
HIF-1 transcriptional activity was followed by measuring the
quantity of one HIF-1 target gene mRNA by real-time RT-PCR.
Under intermittent hypoxia, a progressive increase in aldolase
mRNA level was observed at the third, fourth and fifth periods
of hypoxia (Fig. 10A). On the other hand, in the presence of H-
89, a decrease in aldolase mRNA level was observed (Fig. 10B)
while H-89 did not decrease the increase in aldolase mRNA
levels under chronic hypoxia (data not shown). These results
indicate that phosphorylation of HIF-1α by PKA is important
for HIF-1 transcriptional activity under intermittent hypoxia but
not chronic hypoxia.
HIF-1 transcriptional activity was also studied under hypoxia
using a reporter gene assay (Fig. 11A). A significant increase in
the luciferase activity was observed after incubation of cells
under chronic and intermittent hypoxia with respect to the
normoxic control. The effect of PKA activity inhibition by H-89
Fig. 10. Effect of Hypoxia–Reoxygenation cycles on Aldolase mRNA
expression. (A) EAhy926 endothelial cells were exposed to 4 repeated hypoxia
(1 h)–reoxygenation (30 min) cycles ended by a step of 1 h of hypoxia. mRNA
was extracted after each hypoxia step and retrotranscribed into cDNAwhich was
used to process a real time RT-PCR for Aldolase and α-tubulin using specific
primers. Results are means from two independent experiments. (B) EAhy926
endothelial cells were submitted, in the presence or not of H-89 (at 20 μM), to
5 repeated hypoxia (1 h)–reoxygenation (30 min) cycles ended by a step of
1 h of hypoxia. mRNA was extracted at the end of the kinetics and
retrotranscribed into cDNA which was used to process a real time RT-PCR for
Aldolase and α-tubulin using specific primers. Results are means from three
independent experiments. ⁎⁎⁎pb0.001 vs. HI (Student's t test).
Fig. 11. Effect of Hypoxia–Reoxygenation cycles on HIF-1 transcriptional
activity. (A) EAhy926 endothelial cells were transfected with the pGL3-(PGK-
HRE6)-tk-Luc and pRL normalization vectors. Then the cells were exposed to 5
cycles of hypoxia (1 h)–reoxygenation (30 min) (HI), 7 h or 16 h under chronic
hypoxia (CH) or 7 h under normoxia (N). Thereafter, the cells were incubated
16 h in normoxia in order to allow the synthesis of proteins. Data represent the
ratio between test firefly luciferase activity normalized with the renilla luciferase
activity. Results are presented as means±S.D. for triplicates. ⁎⁎pb0.01 vs.
normoxia (Student's t test). (B) EAhy926 endothelial cells were incubated
during 5.5 h under normoxia (N), intermittent hypoxia (IH) (4 cycles of hypoxia
(1 h)–reoxygenation (30 min)), or chronic hypoxia (CH). After the incubation,
total cell lysates were recovered for western blotting with antibodies against
aldolase and α-tubulin used as loading control.
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reporter system because of interference with the reporter
luciferase expression. These results indicate that HIF-1 is
transcriptionally active under intermittent hypoxia, as already
suggested by the increase in aldolase mRNA level.
In parallel with the reporter gene assay, HIF-1 transcriptional
activity was studied by western blot analysis by following the
abundance of aldolase protein under hypoxia. An increase in the
abundance of aldolase was observed after four cycles of
hypoxia–reoxygenation as well as under chronic hypoxia (Fig.
11B). All together, these results indicate that HIF-1 is
transcriptionally active under intermittent hypoxia.4. Discussion
This study evidenced a modification in HIF-1α phosphor-
ylation pattern under intermittent hypoxia in EAhy926
endothelial cells. Indeed, an increase in the abundance of
HIF-1α phosphorylated form with respect to its non-phos-
phorylated form was observed along with the number of
hypoxia/reoxygenation cycles. This modification in HIF-1α
phosphorylation pattern was also observed in HMEC-1
endothelial cells.
A modification in total abundance of HIF-1α was also
evidenced under intermittent hypoxia at least during the first
three hypoxia/reoxygenation cycles. This increase was
observed in western blot and immunofluorescence analysis.
The gradual increase in the abundance of HIF-1α in the course
of the three first hypoxia/reoxygenation cycles was not an
accumulation of HIF-1α in the course of time. Indeed, during
each reoxygenation step, HIF-1α was completely degraded.
These results suggest an enhanced HIF-1α stabilization at each
of hypoxia period. This observation has also been made in
HUVEC [34].
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poorly described in the literature, contrary to HIF-1α phosphor-
ylation evidenced under chronic hypoxia. Similarly, the
relevance of this phosphorylation under intermittent hypoxia
remains poorly understood.
Several kinases are known to be activated by chronic hypoxia
and at least one of them has been shown to directly phosphorylate
HIF-1α [37,40,41]. We thus wanted to determine the kinase
involved in HIF-1α phosphorylation under intermittent hypoxia.
To this aim, we studied the activation of different kinases and
determined their implication in HIF-1α phosphorylation under
intermittent hypoxia using specific inhibitors.
p42 and p44 MAPKs activation was evidenced in our
experimental conditions. Indeed, after each hypoxia step, an
increase in the abundance of phospho-p42 and phospho-p44 was
observed. This increase was gradual in the course of hypoxia/
reoxygenation cycles and reached itsmaximum at the last hypoxia
step. In the other hand, after each reoxygenation, the phosphor-
ylation decreased, but it never returned to the basal level.
The inhibition of p42 and p44 MAPKs activation by
PD98059 did not affect HIF-1α phosphorylation in our
experimental conditions. These results indicate that p42 and
p44 MAPKs are NOT involved in HIF-1α phosphorylation
under intermittent hypoxia and thus indicate that the pathways
involved in HIF-1α phosphorylation under chronic and
intermittent hypoxia are different. Indeed, Mylonis et al. [41]
showed that p42/p44 MAPKs phosphorylate HIF-1α on serine
641 and serine 643 and that these phosphorylation sites are
needed for HIF-1 transcriptional activity under chronic hypoxia.
The physiological relevance of p42/p44 activation under
intermittent hypoxia, for example for cell survival and/or
proliferation, remains to be elucidated.
PI3K/Akt pathway activation under chronic hypoxia has also
been described in the literature. Moreover, inhibition of this
pathway prevents HIF-1α stabilization under chronic hypoxia
[38,42]. Activation of this pathway was evidenced by Akt. In the
course of hypoxia/reoxygenation cycles, a gradual increase in
the phosphorylation of Akt was observed during the hypoxia
periods. The abundance of phospho-Akt increased after each
hypoxia step and reached its maximum level at the last step of
hypoxia, as observed for phospho-p42 and phospho-p44
MAPKs. On the other hand, each reoxygenation step induced
a partial dephosphorylation of Akt.
Inhibition of this pathway with LY294002 did not prevent
HIF-1α stabilization in our experimental conditions. Moreover,
nomodification inHIF-1α phosphorylation pattern was observed.
This discrepancy could be explained either by difference in cell
type, or by different mechanisms switched on during intermittent
hypoxia in comparison to chronic hypoxia. Indeed, Mottet et al.
showed HIF-1α destabilization under hypoxia in the presence of
LY294002 in hepatomaHepG2 cells [38], while Arsham et al. did
not observe such an effect in glioblastoma cells [43]. As
mentioned before, activation of Akt during the hypoxia period
may play a role in the increase in HIF-1α stabilization. It certainly
has also consequences for cell survival pathways.
Using chemical inhibitors of several kinases, we evidenced
the implication of the PKA in HIF-1α phosphorylation underintermittent hypoxia. Indeed, a modification of HIF-1α
phosphorylation pattern could be observed in the course of
hypoxia/reoxygenation cycles when cells were incubated in the
presence of H-89 (a PKA inhibitor). In the presence of H-89,
the non-phosphorylated form of HIF-1α became predominant
with respect to the phosphorylated form, while without H-89
the phosphorylated form of HIF-1α was predominant. The
reverse was observed in the presence of iloprost, a PKA
activator. This modification in HIF-1α phosphorylation pattern
in the presence of H-89 indicates that PKA is involved in HIF-
1α phosphorylation under intermittent hypoxia. On the other
hand, under chronic hypoxia, H-89 did not affect the HIF-1α
phosphorylation pattern. Therefore, HIF-1α phosphorylation
by PKA would seem to be a specific response under
intermittent hypoxia, but not under chronic hypoxia. This is
coherent with the results of Batmunkh et al. [44] that showed
dbAMP did not enhance HIF-1α protein level under chronic
hypoxia.
It is well established that under hypoxia, intracellular cAMP
concentration can increase [45,46], hence driving PKA
activation. In our experimental conditions, PKA activation
was evidenced. Indeed, a direct kinase assay showed enhanced
PKA activity under intermittent hypoxia in comparison to
normoxic cells. An increased PKA activity has also recently
been observed in murine macrophages exposed to chronic
hypoxia [47]. In parallel, a gradual increase in the phosphoryla-
tion of CREB, a target of PKA, was observed in the course of
hypoxia/reoxygenation cycles while its phosphorylation
decreased when cells were reoxygenated. CREB phosphoryla-
tion under intermittent hypoxia was PKA dependent, because it
was inhibited by H-89. An increase in CREB phosphorylation
was also evidenced after repeated hypoxic exposure in mice
brain [48]. At least two non-exclusive hypotheses can be
proposed to explain the increase in PKA activity observed under
intermittent hypoxia. (i) The activation of the PKA under
intermittent hypoxia could be dependent on adenosine A2
receptor (A2R). Indeed, it was evidenced that hypoxia could
induce the activation of the cAMP-PKA pathway by the A2R in
retinal endothelial cells [49,50]. Hypoxia is known to lead to a
release of endogenous nucleoside adenosine [51]. It was
evidenced recently in HUVEC, that this increase in concentra-
tion of extracellular adenosine under hypoxia is due to a
reduced transport of adenosine by the human Equilibrative
Nucleoside Transporters 1 (hENT1). Indeed, hypoxia can
reduce the adenosine transport velocity of hENT1, as its protein
and mRNA levels [52]. Extracellular adenosine interacts with
the A2R [53] which is a members of the G protein-coupled
receptor family [54]. This receptor is positively linked to
adenylate cyclase [55]. Therefore, A2R activation by adenosine
leads to an increase in cAMP level in PKA activation.
(ii) Another autocrine pathway could also be switched on
under hypoxia, leading to PKA activation. We have previously
shown that when submitted to hypoxic conditions, HUVEC
rapidly release high amount of prostaglandins (PG), amongst
which is prostacyclin [56]. This synthesis is triggered by an
activation of the soluble PLA2 due to an increase in intracellular
calcium concentration [57]. Similarly to adenosine, PGI2 can
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coupled receptor positively linked to the adenylate cyclase [58].
It has to be mentioned that both adenosine and prostaglandin
pathways are coupled since under hypoxia, it has been shown
that adenosine, through interaction with its receptor, increase PG
synthesis, thereby generating cAMP by an autocrine loop
[59,60]. An accumulation of nucleoside adenosine and/or
prostacyclin in the culture medium during the repeated cycles
of hypoxia/reoxygenation could thus lead to a continuous
increase in PKA activity during these cycles and hence to a
parallel increase in HIF-1α phosphorylation. These hypotheses
remain however to be confirmed.
We also investigated if an oxidative stress could be
responsible for the activation during the following hypoxia
period. Based on the articles from Prabhakar's laboratory, we
decided to study the effect of the presence of an antioxidant
during the hypoxia/reoxygenation cycles, on HIF-1alpha
phosphorylation. We used MnTMPyP, a SOD mimetic, at
25 μM as in Yuan et al. [61]. The results show that MnTMPyP
did not affect the increase in HIF-1alpha phosphorylation
observed after 4 cycles of hypoxia/reoxygenation (data not
shown). The experimental conditions used by Yuan et al. were
very different from ours: the length of the hypoxia and the
reoxygenation periods was much smaller : 15 s hypoxia+4 min
reoxygenation 60 or 120 folds in comparison to 60 hypoxia
+30 min reoxygenation from 1 to 4 folds in our work. This may
explain the discrepancy between the two studies.
Ryan et al. [62] reported a p38 MAPK-dependent activation
of NF-kB in bovine aortic endothelial cells. NF-kB activity has
been assayed in our experiment conditions but no activation
could be evidenced while cells responded very well to TNF-α
(data not shown). The experimental conditions used by Ryan et
al. were very different from ours : the length of the hypoxia and
the reoxygenation periods was much smaller : 5 min hypoxia+
10 min reoxygenation from 2 to 16 folds in comparison to 60
hypoxia+30 min reoxygenation from 1 to 4 folds in our work.
This may explain the discrepancy between the two studies.
Indeed, they did observe NF-kB activation but not HIF-1
stabilization (probably because the hypoxia duration was much
too short) while we did demonstrate HIF-1 stabilization. The
signaling pathways initiated in both incubation protocols are
thus probably very different.
HIF-1 is transcriptionally active when in the nucleus. The
nuclear accumulation of HIF-1α under intermittent hypoxia
could explain the increase in HIF-1 transcriptional activity
observed during the hypoxia/reoxygenation cycles, as observed
by the increase in target gene mRNA levels which seem to be
influenced by the PKA activity. The phosphorylation of HIF-1α
can also induce an increase in HIF-1 transcriptional activity
[40,63]. Therefore, the increase in HIF-1α phosphorylated form
with respect to the non-phosphorylated form could synergize
with HIF-1α nuclear accumulation to increase the HIF-1
transcriptional activity under intermittent hypoxia.
We run the HIF-1alpha protein sequence in the NetPhosK
algorithm and found 10 putative PKA phosphorylation sites.
One of them (serine 475) is located in the ODD domain between
the two prolines that can be hydroxylated: phosphorylation ofthis serine may modulate pVHL-ODD domain as it has been
shown for the acetylation of lysine 532 by ARD [64] or the
nitrosylation of cysteine 520 [65], and thus influence HIF-
1alpha stability. Two other putative PKA phosphorylation sites
(serine 760 and serine 808) are located within the C-terminal
transactivation domain : phosphorylation of these serines may
modulate CBP/p300-HIF-1alpha interaction as it has been
shown for the hydroxylation of the arginine 803 by FIH [66]
and the nitrosylation of cysteine 800 [67], and hence influence
HIF-1 transcriptional activity.
The physiologic significance of the progressive HIF-1α
phosphorylation under intermittent hypoxia is not known. On
the other hand, numerous data exist about chronic hypoxia and
the role of HIF-1α phosphorylation. Suzuki et al. [68] proposed
a model, which explains the implication of HIF-1α phosphor-
ylation status for the cell behavior under chronic hypoxia. In
this model, HIF-1αwould have a dual function distinguished by
its phosphorylation status. Indeed, HIF-1α phosphorylated form
will lead to cell survival through the binding of HIF-1α to
ARNT (Aryl hydrocarbon Receptor Nuclear Translocator) and
the increase in the transcription of genes involved in the
adaptation of cells to hypoxia. This process would occur under
mild hypoxia. On the other hand, under prolonged or severe
hypoxia, HIF-1α non-phosphorylated form interacts with p53,
thus leading to p53 stabilization, which would then induce
apoptosis through enhanced Bax expression. In this case, HIF-1
is no longer transcriptionally active.
According to this model, the progressive increase in the
abundance of HIF-1α phosphorylated form observed here
would indicate that intermittent hypoxia would lead, as non-
severe chronic hypoxia, to cell survival. Indeed, we did not
observe any increase in the abundance of p53, nor in cell
death under intermittent hypoxia (data not shown). Moreover,
HIF-1α is transcriptionally active as evidenced by the
increase in HIF-target gene mRNA expression and when
using the HRE-dependent reporter system. Further investiga-
tions are needed to reinforce this hypothesis. In a study run in
parallel to this one, the effect of intermittent hypoxia was
studied on the sensitivity of endothelial cells to radiations.
Martinive et al. [34] showed that intermittent hypoxia reduced
radiation-induced cell death in comparison to cells incubated
under normoxia, thus demonstrating that pre-conditioning is
effective in these conditions. Moreover, this survival effect
was HIF-1-dependent.
In summary, we showed that repeated cycles of hypoxia/
reoxygenation induced a modification in HIF-1α-phosphoryla-
tion pattern in EAhy926 endothelial cells. Activation of p42/
p44 MAPKs, Akt and PKA was observed in these conditions.
The use of inhibitors indicates that PKA was shown to be
involved in the phosphorylation of HIF-1α under intermittent
hypoxia, while p42/p44 MAPKs and Akt were not, and would
seem to influence the HIF-1α transcriptional activity. Some
differences between intermittent hypoxia and chronic hypoxia
were also highlighted regarding phosphorylation pattern as well
as transcriptional activity.
In vivo, tumor endothelial cells exposed to intermittent
hypoxia undergo different stresses. Hypoxia per se reduces cell
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generating difficult survival conditions for cells. The recurrence of
these stresses by repeated hypoxia/reoxygenation cycles would
induce an increase in HIF-1α phosphorylation in endothelial cells
as shown here, which, according to the Suzuki's model, would
lead to cell adaptation to these difficult conditions. It would thus
be more favorable to maintain the new blood vessel network.
Moreover, regarding treatment benefit, the maintenance of blood
vessels in vascularized solid tumor seems to be important for the
efficacy of chemotherapeutic treatments [3], but their destruction
or inhibition of their formation by angiogenic agents could also
induce the regression of tumors [70]. To maintain or to destroy
blood vessels is thus an important issue in cancer treatment. A
better knowledge of the effects of intermittent hypoxia on
endothelial cells and the highlight of particular mechanisms
induced by intermittent hypoxia are thus essential to understand
the behavior of endothelial cells during neo-angiogenesis and to
point important mechanisms in the maintenance or destruction of
tumor vascular network.
Acknowledgments
Sébastien Toffoli is recipient of a FNRS-Télévie grant. Carine
Michiels and Olivier Feron are senior research associates of
FNRS (Fonds National de la Recherche Scientifique, Belgium).
This article presents results of the Belgian Program on In-
teruniversity Poles of Attraction initiated by the Belgian State,
Prime Minister's Office, Science Policy Programming. The
responsibility is assumed by its authors. We are grateful to Prof.
C. Edgell (Pathology Department, University of North Carolina)
for kindly donating the EAhy926 cells and to Prof. P. Ratcliffe
(Institute of Molecular Medicine, John Radcliffe Hospital,
Oxford) for giving us the pGL3(PGK-HRE6)-tk-Luc plasmid.
References
[1] R.K. Jain, Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy, Science 307 (2005) 58–62.
[2] G.M. Tozer, C. Kanthou, B.C. Baguley, Disrupting tumour blood vessels,
Nat. Rev., Cancer 5 (2005) 423–435.
[3] P. Carmeliet, R.K. Jain, Angiogenesis in cancer and other diseases, Nature
407 (2000) 249–257.
[4] C.W. Pugh, P.J. Ratcliffe, Regulation of angiogenesis by hypoxia: role of
the HIF system, Nat. Med. 9 (2003) 677–684.
[5] D. Lyden, K. Hattori, S. Dias, C. Costa, P. Blaikie, L. Butros, A. Chadburn,
B. Heissig, W. Marks, L. Witte, Y. Wu, D. Hicklin, Z. Zhu, N.R. Hackett,
R.G. Crystal, M.A. Moore, K.A. Hajjar, K. Manova, R. Benezra, S. Rafii,
Impaired recruitment of bone-marrow-derived endothelial and hemato-
poietic precursor cells blocks tumor angiogenesis and growth, Nat. Med. 7
(2001) 1194–1201.
[6] Y. Dor, R. Porat, E. Keshet, Vascular endothelial growth factor and vascular
adjustments to perturbations in oxygen homeostasis, Am. J. Physiol., Cell
Physiol. 280 (2001) C1367–C1374.
[7] R. Kerbel, J. Folkman, Clinical translation of angiogenesis inhibitors, Nat.
Rev., Cancer 2 (2002) 727–739.
[8] G. Bergers, L.E. Benjamin, Tumorigenesis and the angiogenic switch, Nat.
Rev., Cancer 3 (2003) 401–410.
[9] A. Eberhard, S. Kahlert, V. Goede, B. Hemmerlein, K.H. Plate, H.G.
Augustin, Heterogeneity of angiogenesis and blood vessel maturation in
human tumors: implications for antiangiogenic tumor therapies, Cancer
Res. 60 (2000) 1388–1393.[10] L.E. Benjamin, D. Golijanin, A. Itin, D. Pode, E. Keshet, Selective
ablation of immature blood vessels in established human tumors follows
vascular endothelial growth factor withdrawal, J. Clin. Invest. 103 (1999)
159–165.
[11] S. Morikawa, P. Baluk, T. Kaidoh, A. Haskell, R.K. Jain, D.M. McDonald,
Abnormalities in pericytes on blood vessels and endothelial sprouts in
tumors, Am. J. Pathol. 160 (2002) 985–1000.
[12] R.E. Dur, C. Aquino-Parsons, Clinical relevance of intermittent tumour
blood flow, Acta Oncol. 40 (2001) 929–936.
[13] R.E. Dur, C. Aquino-Parsons, Non-constant tumour blood flow-implica-
tions for therapy, Acta Oncol. 40 (2001) 862–869.
[14] K.L. Bennewith, R.E. Durand, Quantifying transient hypoxia in human
tumor xenografts by flow cytometry, Cancer Res. 64 (2004) 6183–6189.
[15] J.W. Baish, R.K. Jain, Fractals and cancer, Cancer Res. 60 (2000)
3683–3688.
[16] T.P. Padera, B.R. Stoll, J.B. Tooredman, D. Capen, E. di Tomaso, R.K.
Jain, Pathology: cancer cells compress intratumour vessels, Nature 427
(2004) 695.
[17] R.H. Wenger, Cellular adaptation to hypoxia: O2-sensing protein
hydroxylases, hypoxia-inducible transcription factors, and O2-regulated
gene expression, FASEB J. 16 (2002) 1151–1162.
[18] G.L. Wang, B.H. Jiang, E.A. Rue, G.L. Semenza, Hypoxia-inducible
factor 1 is a basic-helix–loop–helix–PAS heterodimer regulated by
cellular O2 tension, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5510–5514.
[19] G.L. Wang, G.L. Semenza, Purification and characterization of hypoxia-
inducible factor 1, J. Biol. Chem. 270 (1995) 1230–1237.
[20] S. Salceda, J. Caro, Hypoxia-inducible factor 1alpha (HIF-1alpha) protein
is rapidly degraded by the ubiquitin–proteasome system under normoxic
conditions. Its stabilization by hypoxia depends on redox-induced changes,
J. Biol. Chem. 272 (1997) 22642–22647.
[21] G.L. Semenza, HIF-1, O(2), and the 3 PHDs: how animal cells signal
hypoxia to the nucleus, Cell 107 (2001) 1–3.
[22] M. Ivan, K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J.M.
Asara, W.S. Lane, W.G. Kaelin Jr., HIFalpha targeted for VHL-mediated
destruction by proline hydroxylation: implications for O2 sensing, Science
292 (2001) 464–468.
[23] M.E. Cockman, N. Masson, D.R. Mole, P. Jaakkola, G.W. Chang, S.C.
Clifford, E.R. Maher, C.W. Pugh, P.J. Ratcliffe, P.H. Maxwell, Hypoxia
inducible factor-alpha binding and ubiquitylation by the von Hippel–
Lindau tumor suppressor protein, J. Biol. Chem. 275 (2000) 25733–25741.
[24] P. Jaakkola, D.R. Mole, Y.M. Tian, M.I. Wilson, J. Gielbert, S.J. Gaskell,
A. Kriegsheim, H.F. Hebestreit, M. Mukherji, C.J. Schofield, P.H.
Maxwell, C.W. Pugh, P.J. Ratcliffe, Targeting of HIF-alpha to the von
Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydro-
xylation, Science 292 (2001) 468–472.
[25] U.R. Jewell, I. Kvietikova, A. Scheid, C. Bauer, R.H. Wenger, M.
Gassmann, Induction of HIF-1alpha in response to hypoxia is instanta-
neous, FASEB J. 15 (2001) 1312–1314.
[26] B.H. Jiang, E. Rue, G.L. Wang, R. Roe, G.L. Semenza, Dimerization,
DNA binding, and transactivation properties of hypoxia-inducible factor 1,
J. Biol. Chem. 271 (1996) 17771–17778.
[27] R.H. Wenger, Mammalian oxygen sensing, signalling and gene regulation,
J. Exp. Biol. 203 (2000) 1253–1263.
[28] R.E. Durand, Intermittent blood flow in solid tumours—An under-
appreciated source of ‘drug resistance’, Cancer Metastasis Rev. 20 (2001)
57–61.
[29] J. Denekamp, A. Dasu, Inducible repair and the two forms of tumour
hypoxia-time for a paradigm shift, Acta Oncol. 38 (1999) 903–918.
[30] D.J. Chaplin, S.A. Hill, Temporal heterogeneity in microregional
erythrocyte flux in experimental solid tumours, Br. J. Cancer 71 (1995)
1210–1213.
[31] M.W. Dewhirst, R.D. Braun, J.L. Lanzen, Temporal changes in PO2 of
R3230AC tumors in Fischer-344 rats, Int. J. Radiat. Oncol. Biol. Phys. 42
(1998) 723–726.
[32] S.A. Hill, K.H. Pigott, M.I. Saunders, M.E. Powell, S. Arnold, A. Obeid,
G. Ward, M. Leahy, P.J. Hoskin, D.J. Chaplin, Microregional blood flow in
murine and human tumours assessed using laser Doppler microprobes, Br.
J. Cancer., Suppl. 27 (1996) S260–S263.
1571S. Toffoli et al. / Biochimica et Biophysica Acta 1773 (2007) 1558–1571[33] K.H. Pigott, S.A. Hill, D.J. Chaplin, M.I. Saunders, Microregional
fluctuations in perfusion within human tumours detected using laser
Doppler flowmetry, Radiother. Oncol. 40 (1996) 45–50.
[34] P. Martinive, F. Defresne, C. Bouzin, J. Saliez, F. Lair, V. Gregoire, C.
Michiels, C. Dessy, O. Feron, Preconditioning of the tumor vasculature
and tumor cells by intermittent hypoxia: implications for anticancer
therapies, Cancer Res. 66 (2006) 11736–11744.
[35] C.J. Edgell, C.C. McDonald, J.B. Graham, Permanent cell line expressing
human factor VIII-related antigen established by hybridization, Proc. Natl.
Acad. Sci. U. S. A. 80 (1983) 3734–3737.
[36] P.H. Maxwell, M.S. Wiesener, G.W. Chang, S.C. Clifford, E.C. Vaux, M.E.
Cockman, C.C. Wykoff, C.W. Pugh, E.R. Maher, P.J. Ratcliffe, The
tumour suppressor protein VHL targets hypoxia-inducible factors for
oxygen-dependent proteolysis, Nature 399 (1999) 271–275.
[37] E. Minet, T. Arnould, G. Michel, I. Roland, D. Mottet, M. Raes, J.
Remacle, C. Michiels, ERK activation upon hypoxia: involvement in HIF-
1 activation, FEBS Lett. 468 (2000) 53–58.
[38] D. Mottet, V. Dumont, Y. Deccache, C. Demazy, N. Ninane, M. Raes, C.
Michiels, Regulation of hypoxia-inducible factor-1alpha protein level
during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/
glycogen synthase kinase 3beta pathway in HepG2 cells, J. Biol. Chem.
278 (2003) 31277–31285.
[39] C. Treins, S. Giorgetti-Peraldi, J. Murdaca, M.N. Monthouel-Kartmann, E.
Van Obberghen, Regulation of hypoxia-inducible factor (HIF)-1 activity
and expression of HIF hydroxylases in response to insulin-like growth
factor I, Mol. Endocrinol. 19 (2005) 1304–1317.
[40] D.E. Richard, E. Berra, E. Gothie, D. Roux, J. Pouyssegur, p42/p44
mitogen-activated protein kinases phosphorylate hypoxia-inducible factor
1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1,
J. Biol. Chem. 274 (1999) 32631–32637.
[41] I. Mylonis, G. Chachami, M. Samiotaki, G. Panayotou, E. Paraskeva, A.
Kalousi, E. Georgatsou, S. Bonanou, G. Simos, Identification of MAPK
phosphorylation sites and their role in the localization and activity of
hypoxia-inducible factor-1alpha, J. Biol. Chem. 281 (2006) 33095–33106.
[42] J. Zhou, T. Schmid, R. Frank, B. Brune, PI3K/Akt is required for heat
shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-
independent degradation, J. Biol. Chem. 279 (2004) 13506–13513.
[43] A.M. Arsham, D.R. Plas, C.B. Thompson, M.C. Simon, Phosphatidyli-
nositol 3-kinase/Akt signaling is neither required for hypoxic stabilization
of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcrip-
tion, J. Biol. Chem. 277 (2002) 15162–15170.
[44] C. Batmunkh, J. Krajewski, W. Jelkmann, T. Hellwig-Burgel, Erythro-
poietin production: Molecular mechanisms of the antagonistic actions of
cyclic adenosine monophosphate and interleukin-1, FEBS Lett. 580 (2006)
3153–3160.
[45] I. Kvietikova, R.H. Wenger, H.H. Marti, M. Gassmann, The transcription
factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible
factor-1 (HIF-1) DNA recognition site, Nucleic Acids Res. 23 (1995)
4542–4550.
[46] H.H. Marti, H.H. Jung, J. Pfeilschifter, C. Bauer, Hypoxia and cobalt
stimulate lactate dehydrogenase (LDH) activity in vascular smooth muscle
cells, Pflugers Arch. 429 (1994) 216–222.
[47] S.K. Prabu, H.K. Anandatheerthavarada, H. Raza, S. Srinivasan, J.F.
Spear, N.G. Avadhani, Protein kinase A-mediated phosphorylation
modulates cytochrome C oxidase function and augments hypoxia and
myocardial ischemia related injury, J. Biol. Chem. 281 (2005) 2061–2070.
[48] Y. Gao, G. Gao, C. Long, S. Han, P. Zu, L. Fang, J. Li, Enhanced
phosphorylation of cyclic AMP response element binding protein in the
brain of mice following repetitive hypoxic exposure, Biochem. Biophys.
Res. Commun. 340 (2006) 661–667.
[49] H. Takagi, G.L. King, N. Ferrara, L.P. Aiello, Hypoxia regulates vascular
endothelial growth factor receptor KDR/Flk gene expression through
adenosine A2 receptors in retinal capillary endothelial cells, Investig.
Ophthalmol. Vis. Sci. 37 (1996) 1311–1321.
[50] H. Takagi, G.L. King, G.S. Robinson, N. Ferrara, L.P. Aiello, Adenosine
mediates hypoxic induction of vascular endothelial growth factor in retinalpericytes and endothelial cells, Investig. Ophthalmol. Vis. Sci. 37 (1996)
2165–2176.
[51] J.M. Marshall, Adenosine and muscle vasodilatation in acute systemic
hypoxia, Acta Physiol. Scand. 168 (2000) 561–573.
[52] P. Casanello, A. Torres, F. Sanhueza, M. Gonzalez, M. Farias, V. Gallardo,
M. Pastor-Anglada, R. San Martin, L. Sobrevia, Equilibrative nucleoside
transporter 1 expression is downregulated by hypoxia in human umbilical
vein endothelium, Circ. Res. 97 (2005) 16–24.
[53] T.H. Adair, Growth regulation of the vascular system: an emerging role for
adenosine, Am. J. Physiol., Regul. Integr. Comp. Physiol. 289 (2005)
R283–R296.
[54] B.B. Fredholm, M.P. Abbracchio, G. Burnstock, J.W. Daly, T.K. Harden,
K.A. Jacobson, P. Leff, M. Williams, Nomenclature and classification of
purinoceptors, Pharmacol. Rev. 46 (1994) 143–156.
[55] J.L. Daval, F. Nicolas, J.F. Doriat, Adenosine physiology and pharmacol-
ogy: how about A2 receptors? Pharmacol. Ther. 71 (1996) 325–335.
[56] C. Michiels, T. Arnould, I. Knott, M. Dieu, J. Remacle, Stimulation of
prostaglandin synthesis by human endothelial cells exposed to hypoxia,
Am. J. Physiol. 264 (1993) C866–C874.
[57] C. Michiels, P. Renard, N. Bouaziz, N. Heck, F. Eliaers, N. Ninane, R.
Quarck, P. Holvoet, M. Raes, Identification of the phospholipase A(2)
isoforms that contribute to arachidonic acid release in hypoxic endothelial
cells: limits of phospholipase A(2) inhibitors, Biochem. Pharmacol. 63
(2002) 321–332.
[58] K. Tsuboi, Y. Sugimoto, A. Ichikawa, Prostanoid receptor subtypes,
Prostaglandins Other Lipid Mediat. 68–69 (2002) 535–556.
[59] C.J. Ray, M.R. Abbas, A.M. Coney, J.M. Marshall, Interactions of
adenosine, prostaglandins and nitric oxide in hypoxia-induced vasodilata-
tion: in vivo and in vitro studies, J. Physiol. 544 (2002) 195–209.
[60] C.J. Ray, J.M. Marshall, The cellular mechanisms by which adenosine
evokes release of nitric oxide from rat aortic endothelium, J. Physiol. 570
(2006) 85–96.
[61] G. Yuan, G. Adhikary, A.A. McCormick, J.J. Holcroft, G.K. Kumar, N.R.
Prabhakar, Role of oxidative stress in intermittent hypoxia-induced
immediate early gene activation in rat PC12 cells, J. Physiol. 557 (2004)
773–783.
[62] S. Ryan, W.T. McNicholas, C.T. Taylor, A critical role for p38 map kinase
in NF-kappaB signaling during intermittent hypoxia/reoxygenation,
Biochem. Biophys. Res. Commun. 355 (2007) 728–733.
[63] H. Zhong, K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M.M.
Georgescu, J.W. Simons, G.L. Semenza, Modulation of hypoxia-inducible
factor 1alpha expression by the epidermal growth factor/phosphatidylino-
sitol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells:
implications for tumor angiogenesis and therapeutics, Cancer Res. 60
(2000) 1541–1545.
[64] J.W. Jeong, M.K. Bae, M.Y. Ahn, S.H. Kim, T.K. Sohn, M.H. Bae, M.A.
Yoo, E.J. Song, K.J. Lee, K.W. Kim, Regulation and destabilization of
HIF-1alpha by ARD1-mediated acetylation, Cell 111 (2002) 709–720.
[65] F. Li, P. Sonveaux, Z.N. Rabbani, S. Liu, B. Yan, Q. Huang, Z. Vujaskovic,
M.W. Dewhirst, C.Y. Li, Regulation of HIF-1alpha stability through S-
nitrosylation, Mol. Cell 26 (2007) 63–74.
[66] D. Lando, D.J. Peet, J.J. Gorman, D.A. Whelan, M.L. Whitelaw, R.K.
Bruick, FIH-1 is an asparaginyl hydroxylase enzyme that regulates the
transcriptional activity of hypoxia-inducible factor, Genes Dev. 16 (2002)
1466–1471.
[67] I.M. Yasinska, V.V. Sumbayev, S-nitrosation of Cys-800 of HIF-1alpha
protein activates its interaction with p300 and stimulates its transcriptional
activity, FEBS Lett. 549 (2003) 105–109.
[68] H. Suzuki, A. Tomida, T. Tsuruo, Dephosphorylated hypoxia-inducible
factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia,
Oncogene 20 (2001) 5779–5788.
[69] A.M. Vexler, L.L. Litinskaya, Changes in intracellular pH induced by
hyperthermia and hypoxia, Int. J. Hypertherm. 2 (1986) 75–81.
[70] T. Nakamura, S. Ozawa, Y. Kitagawa, M. Ueda, T. Kubota, M. Kitajima,
Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted
A-431 cells, Oncol. Rep. 15 (2006) 79–83.
